Ex Parte ETCHEVERRY et al - Page 7


              Appeal No.  2002-0872                                                         Page 7                      
              Application No.  08/470,849                                                                               
                                                                                                                       
                     the prosecution history (sometimes called "file wrapper and contents") of                          
                     the patent consists of the entire record of proceedings in the Patent and                          
                     Trademark Office.  This includes all express representations made by or                            
                     on behalf of the applicant to the examiner to induce a patent grant, or, as                        
                     here, to reissue a patent.  Such representations include amendments to                             
                     the claims and arguments made to convince the examiner that the                                    
                     claimed invention meets the statutory requirements of novelty, utility, and                        
                     nonobviousness.  Thus, the prosecution history (or file wrapper) limits the                        
                     interpretation of claims so as to exclude any interpretation that may have                         
                     been disclaimed or disavowed during prosecution in order to obtain claim                           
                     allowance.                                                                                         
              In our opinion, appellants limited the interpretation of their claimed invention to a human               
              TNFR1 – human IgG1 preparation, by amending their claimed invention to include the                        
              term “human” in front of the term TNFR1-IgG1 (see Paper No. 8, page 2), and by                            
              arguing that their claimed invention is limited to human TNFR1 – human IgG1                               
              preparations (see Paper No. 8, page 6, and Brief, page 11).  Accordingly, the human-                      
              mouse construct disclosed by Beutler does not anticipate the claimed invention.                           
                     We recognize the examiner argument (Answer, page 12), “[t]he claims are not                        
              limited to a specific species with a specific amino acid sequence, but is [sic] encompass                 
              a genus of ‘human TNFR1-IgG’ whose amino acid sequence is not limited.”  The                              
              examiner, however, has not explained why the absence of amino acid sequence                               
              information would have any effect in the determination of whether a chimeric human-                       
              mouse fusion protein anticipates a human fusion protein as set forth in the specification                 
              and claims (e.g., claim 18, “[a] human TNFR1-IgG1 preparation….”).  “A claim is                           
              anticipated only if each and every element as set forth in the claim is found, either                     
              expressly or inherently described, in a single prior art reference.”  Verdegaal Bros., Inc.               
              v. Union Oil Co., 814 F.2d 628, 631, 2 USPQ2d 1051, 1053 (Fed. Cir. 1987);  In re                         
              Schreiber, 128 F.3d 1473, 1477, 44 USPQ2d 1429, 1431 (Fed. Cir. 1997).   It is                            







Page:  Previous  1  2  3  4  5  6  7  8  9  Next 

Last modified: November 3, 2007